A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome.
A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome.
复制标题
氢化可的松治疗呼吸窘迫综合征婴儿的对照试验。
作者：
M. Baden;C. Bauer;E. Colle;G. Klein;Taeusch Hw;L. Stern
在一项对照研究中，44名婴儿接受氢化可的松或乳糖安慰剂治疗，以评估出生后给予氢化可的松改变呼吸窘迫综合征（RDS）婴儿病程或结局的能力。未证实对PaO 2、PaCO 2、[H+]、所需环境氧百分比、A-aDO 2梯度、辅助通气需求或存活率的显著影响。给药后72小时内，氢化可的松和安慰剂治疗婴儿的血浆皮质类固醇水平存在显著差异。对24例RDS婴儿与10例对照早产儿血浆皮质类固醇水平的进一步分析未能证明RDS婴儿存在任何内源性皮质类固醇缺乏。虽然没有发现治疗的直接有害影响，但出生后使用皮质类固醇似乎对RDS婴儿没有任何明显的益处。
Forty-four infants were treated with hydrocortisone or a lactose placebo in a controlled study to evaluate the ability of postnatally administered hydrocortisone to alter the course or outcome in infants with the Respiratory Distress Syndrome (RDS). No significant effect on PaO2, PaCO2, [H+], percent ambient oxygen needed, A-aDO2 gradients, need for assisted ventilation, or survival was demonstrated. Plasma corticosteroids during the 72-hour period after administration showed significant differences between the hydrocortisone- and placebo-treated infants. Additional analysis of plasma corticosteroid levels in 24 RDS infants versus 10 control prematures failed to demonstrate any endogenous deficiency of corticosteroids in infants with RDS. Although no immediate detrimental effects of the therapy were seen, the postnatal use of corticosteroids did not appear to carry any obvious benefit for the infant with RDS.